Gannex Announces the Completion of Patient Enrollment for Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis ...Middle East

-- Gannex is expected to release topline data of the Phase II clinical trial by the end of 2023 SHANGHAI, July 19, 2023 /PRNewswire/ -- Gannex Pharma Co., Ltd. ("Gannex"), a wholly-owned company of Ascletis Pharma Inc. (HKEX:1672) announces today the completion of enrollment of 98...

Hence then, the article about gannex announces the completion of patient enrollment for phase ii clinical trial of asc42 an fxr agonist for primary biliary cholangitis was published today ( Thursday 20/07/2023 - 03:20 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Gannex Announces the Completion of Patient Enrollment for Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis )

Also on site :

• U.S. government is spending $88 billion a month in interest on national debt—equal to spending on defense and education combined
• Goldfish Is Offering Fans Free Crackers for Tax Day—Here’s How To Claim Yours
• Cannes: Studiocanal Boards Jeanne Herry’s Palme D’Or Contender ‘Another Day’ & Unveils First Look